Physician profile
Eric Woolley
NPI 1043231749
$693.66
in general payments reported to CMS, 2019-2025
12 companies · $47.42 in 2025
The $47.42 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $17.43 · 2021: $98.25 · 2022: $16.49 · 2023: $16.83 · 2024: $191 · 2025: $47.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $202.52 | 2019-2021 | |
| Penumbra, INC. | $119.47 | 2024 | Indigo System |
| Pfizer INC. | $80.74 | 2022-2025 | |
| Abbvie INC. | $79.21 | 2021 | |
| Haemonetics Corporation | $66.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $44.42 | 2024 | Andexxa |
| Kestra Medical Technology Services, INC. | $26.83 | 2024 | Assure Wcd |
| Allergan, INC. | $17.43 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.41 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.28 | 2019 | |
| Genentech USA, INC. | $13.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Woolley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.